Skip to main content
Premium Trial:

Request an Annual Quote

Evogene Raises Another $1.5M in Second Closing of Initial Placement

NEW YORK, Feb. 24 (GenomeWeb News) - Evogene has raised another $1.5 million in a second closing of its first private placement, the company said today.


The second closing brings the total amount of the first round to $3.5 million, after the first closing in March of 2003.


Evogene, based in Rehovot, Israel, combines predictive computational biology and plant genomics with classical breeding technologies to generate improved crops. The company was spun out of Compugen in 2002.


The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.